Patients Furious, FDA Doubles Down

The strongest reading of the record is not that the FDA was captured by “leftwing influence,” but that Vinay Prasad became the face of a more exacting evidentiary regime in rare disease regulation—one that many patients and sponsors experienced as denial, while its defenders saw it as overdue discipline.

Intro Header

Prasad’s tenure at CBER was defined by high-friction decisions on rare disease therapies, especially in cell and gene therapy.
The public record supports a dispute over standards and timing, not proof of political bias.
Prasad’s critics point to Complete Response Letters and reversals that felt like moving the goalposts; his defenders point to safety signals, weak comparators, and his own history of criticizing lax approvals.
The most durable conclusion is that rare disease regulation sits on a fault line between access and evidentiary rigor, and Prasad’s style made that fault line visible.

The real question is standards, not slogans

Rare disease drug development is structurally hard: patient populations are tiny, natural history is variable, and randomized controlled trials are often difficult or ethically awkward to run. That is exactly why the FDA has long used orphan-drug incentives, surrogate endpoints, and other regulatory flexibilities to keep the field alive. The controversy around Prasad is that, in the eyes of sponsors and patient advocates, he treated that flexibility as something to be earned repeatedly rather than assumed once a program had reached late-stage review. In the eyes of his defenders, that is not ideological hostility; it is the minimum discipline required when the products in question are powerful, expensive, and sometimes risky.

The evidence package does not show internal documents proving “leftwing influence” drove those decisions. What it does show is a series of contentious denials and restrictions tied to rare disease therapies, along with a public backlash from companies, investors, and advocates who believed the agency was changing its expectations late in the process. That is a serious charge, but it is not the same thing as proof of political manipulation. The more defensible claim is narrower: under Prasad, the FDA’s biologics center became more willing to say no, and that shift landed hardest on programs for which the usual trial architecture was already fragile.

How Prasad’s FDA approach actually worked

Prasad did not arrive as a blank slate. Long before his FDA post, he had built a reputation for criticizing approvals that rested on surrogate endpoints rather than clear clinical benefit; his published work on cancer drugs found that a large share of approvals on surrogates had unknown survival effects or failed to improve survival at all. That background matters because it explains the governing instinct behind his FDA decisions. He is not, on the available record, a reflexive blocker of innovation. He is a regulator who believes the burden of proof should rise when a therapy is novel, invasive, or likely to expose fragile patients to serious harm.

That instinct shows up plainly in the rare disease cases cited in the research package. The FDA rejected Pierre Fabre’s tabelecleucel application for Ebvallo, an ultra-rare lymphoma therapy, and the reporting around that decision emphasizes the agency’s demand for a randomized controlled trial despite the practical difficulty of running one in such a small population. That is the heart of the conflict. Sponsors and advocates saw an impossible evidentiary bar; the FDA, at least as represented in the available reporting, saw insufficient proof. Likewise, on Elevidys, the FDA’s intervention followed three patient deaths and safety concerns around gene therapy, not a vague ideological dislike of the platform.

Why patient groups read this as abandonment

For families living with rare disease, regulatory nuance often collapses into a brutal practical reality: if a therapy is denied or delayed, there may be no alternative. That is why the language in the coverage is so combustible. Companies called some of the letters unexpected. Advocates described inconsistent standards. Analysts went so far as to frame Prasad’s exit as a “big win” for biotech and for rare disease companies in particular. In that ecosystem, a refusal letter is not merely a regulatory document; it is the difference between a shot at treatment and another year of waiting.

Yet the emotional force of that position does not itself establish political causation. The record also contains evidence that Prasad had already built an anti-laxity philosophy before entering the agency, which cuts against the idea that his decisions were a new ideological import from the left or from any other political camp. His public remarks and his published work point toward a consistent regulatory thesis: many approvals, especially in high-uncertainty settings, advance faster than the evidence justifies. In other words, the through line is epistemic, not partisan. He is arguing about how much uncertainty society should tolerate before allowing a therapy onto the market.

The strongest counterargument: he was not a rigid absolutist

The best evidence against the caricature of Prasad as an inflexible “RCT absolutist” is that he published a framework for ultra-rare diseases where randomized trials are infeasible, and the FDA under his orbit also approved bespoke therapies, including a one-patient gene-editing case for a neonatal-onset metabolic disorder. That matters because it complicates the easy story line that he wanted one universal evidentiary template applied mechanically to every rare disease. The record instead suggests something more selective: he was willing to innovate on method when the disease biology and trial constraints made that unavoidable, but he was not prepared to let rarity itself become a substitute for proof.

This is the key point lost when Prasad is reduced to a villain or savior. The rare disease field does not need a regulator who blindly says yes, because the history of medicine is full of therapies that looked compelling before better evidence exposed weak benefit or real harm. Nor does it benefit from a regulator who demands perfect evidence where perfect evidence is impossible. The difficult, adult answer is that the FDA must continuously negotiate between those poles. Prasad’s tenure is controversial because he pushed hard toward the proof side of that balance, and the people harmed by delay experience that push as abandonment.

$qure $clpt

Good article by @maxonwifi

Notably, the names of the previous agency leaders were never mentioned specifically. At one point, Crowley asked whether Mikhail’s predecessor, Vinay Prasad, was the barrier between what review teams decided and what guidance was…

— mike (@mike98572986) June 25, 2026

What the evidence does and does not support about “leftwing influence”

The phrase “leftwing influence” does not earn its place as an evidence-based conclusion from the material provided. The files here contain frustration, backlash, and claims of arbitrary decision-making; they do not contain internal communications, named political directives, or sworn testimony showing partisan interference. That absence matters. If political influence existed, the public package does not prove it. What it does prove is that Prasad’s choices collided with a rare disease sector already primed to interpret strictness as betrayal, especially after years in which the FDA had often been criticized for being too permissive on accelerated pathways and surrogate-based approvals.

The more rigorous interpretation is that Prasad was not leaving rare disease patients behind because of ideology imported from the left, but because he believed the agency had to reassert evidentiary discipline after years of permissive drift. Whether that makes him right is a separate question from whether he was partisan. On the current record, the partisan claim is unproven; the regulatory conflict is real, and it is substantial.

What this means for rare disease regulation going forward

The enduring lesson is that rare disease policy cannot survive on aspiration alone. Sponsors need advance notice of what evidence will be acceptable; patients need speed; regulators need room to stop a program when safety deteriorates or efficacy is too thin. The recent controversy exposed how easily those goals collide when guidance shifts late in development or when a sponsor believes prior FDA advice has been abandoned without a clear public explanation. That is why transparency is not a slogan here; it is the only way to keep hard-edged regulatory judgment from being mistaken for politics.

Prasad’s tenure also shows why the FDA’s internal philosophy matters so much. A center director who prizes evidentiary rigor will inevitably be called hostile by people who live downstream of delays. A director who prizes access will inevitably be accused of lowering the bar. Rare disease regulation sits in that tension permanently. The best systems do not pretend the tension can be eliminated. They make the standards legible, keep the rationale public, and accept that in a field where most diseases still lack approved treatments, the difference between rigor and obstruction is often narrower in rhetoric than it is in evidence.